SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF PNEUMOCOCCAL CONJUGATE VACCINES IN EAST AND SOUTHEAST ASIA (ID 241)
- Matt Wasserman, United States of America
- Bruce Wang, United States of America
- Nathorn Chaiyakunapruk, United States of America
- Kun Zhao, China
- Shuiqing Zhu, China
- Joseph Babigumira, United States of America
- Wes Furnback, United States of America
- Ramaa Chitale, United States of America
- Amgad Gamil, Singapore
- Matt Wasserman, United States of America
Abstract
Background
Pneumococcal conjugate vaccines (PCVs) reduced the incidence of pneumococcal disease. We performed a systematic literature review of the cost-effectiveness of PCVs within East and Southeast Asia.
Methods
We reviewed the MEDLINE and EMBASE databases through 10/11/2019 to identify studies evaluating the cost-effectiveness of PCVs in East and Southeast Asia. Study characteristics, clinical outcomes, cost outcomes, and cost-effectiveness results were extracted, while studies without at least one analysis in East and Southeast Asia were excluded.
Results
We included 32 studies: 3 multi-setting studies and 29 single-setting studies. Within these studies, there were a total of 55 separate analyses comparing pneumococcal vaccination strategies. A PCV (PCV7/10/13) was compared to no vaccination in 45 (81.8%) analyses, and the vaccine was considered cost-effective in 86.7% (39/45) (Table 1). PCV13 and PCV10 were evaluated in 9 (16.4%) analyses. The results comparing PCV10 with PCV13 were heavily dependent on the study funder and modeling assumptions but independent studies found PCV13 cost-effective compared to PCV10 due to broader serotype coverage.
Conclusions
PCVs are generally cost-effective against no vaccination in Asia. This study will support decision-makers in Asia as they consider the clinical and economic value of introducing PCV NIPs and considering higher valent vaccines.